Last reviewed · How we verify
NCT06621485
Calculator Predicts Early Mortality Post Hepatocellular Carcinoma Resection
trial in To Predict Early Post-hepatectomy Mortality for HCC in 4,966 participants. Completed in 31 March 2024.
15 March 2024
Quick facts
| Lead sponsor | Beijing Tsinghua Chang Gung Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 4,966 |
| Start date | 15 February 2024 |
| Primary completion | 15 March 2024 |
| Estimated completion | 31 March 2024 |
| Sites | 1 location across China |
Conditions studied
- To Predict Early Post-hepatectomy Mortality for HCC — all drugs for To Predict Early Post-hepatectomy Mortality for HCC →
Sponsor
Beijing Tsinghua Chang Gung Hospital
Who can join
18 and older, any sex, with To Predict Early Post-hepatectomy Mortality for HCC. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Using the multicenter data, we developed and validated an individualized online calculator to predict early mortality after liver resection for hepatocellular carcinoma. The user-friendly tool with 6 preoperative predictors demonstrated excellent accuracy. The freely available calculator may help identify high-risk patients and reduce futile liver resection for hepatocellular carcinoma.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06621485
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Beijing Tsinghua Chang Gung Hospital trials
Trials by the same sponsor.
- NCT07123675 — AI-Assisted Blood Pressure Control During Anesthesia · NA · not yet recruiting
- NCT07152496 — Host-Microbe Interactions in Biliary Dilatation · not yet recruiting
- NCT07330271 — PTC-Guided Therapy for Peritoneal Mesothelioma · NA · recruiting
- NCT07328737 — One vs Three HIPEC Cycles After CRS for Pseudomyxoma Peritonei · NA · recruiting
- NCT07044947 — Oteseconazole in the Treatment of Adults With Vulvovaginal Candidiasis（VVC） · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06621485 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing Tsinghua Chang Gung Hospital
- Last refreshed: 1 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06621485.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing